Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (41) clinical trials

Samples From Leukemia Patients and Their Donors to Identify Specific Antigens

It is well known that tumor cells and leukemia cells express different surface structures (called antigens) that can serve as targets for cancer cell destruction by the immune system. Effective immune therapies are characterized by high specificity and low toxicity. One of the major obstacles impeding the use of these ...

Phase N/A

Sorafenib to Treat FLT3-ITD AML

It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 ...

Phase N/A

Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is now an effective treatment of Acute Myeloid Leukemia (AML). After allo-HSCT, relapses are the major cause of mortality and occur in about 30% of cases. The occurrence of relapses is important during the first three months post-allogeneic transplant, then gradually decreases during the ...

Phase N/A

Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias

Hematopoietic stem cell transplantation (HSCT) is the most effective treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), with the lowest rates of relapse. Fertility rate in Brazil is falling, and only 25% of people born today will have a matched sibling donor. On the other hand, currently ...

Phase N/A

Epidemiologic Registry PETHEMA LMA 2015

To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice ...

Phase N/A

VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years

Approximately in 6 months, collect and review the retrospective data. During this period, and in order to ensure an excellent quality of the collected data, perform constant monitoring and real-time data received in 2 phases: Monitoring "in situ" in the focal point: once the information is received before shall enter ...

Phase N/A

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

This is a prospective non-therapeutic study, assessing the long-term toxicity of pediatric HCT for hematologic malignancies. This study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC), the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Transplant Program (NMDP) and the Resource for ...

Phase N/A

Home Away From Home - Medical Outcomes

This is a bidirectional observational cohort study. Participants will be patients 18 years of age or younger at diagnosis receiving or having received chemotherapy for AML from fifteen participating pediatric hospitals across the United States. There is no study intervention; this is a medical record abstraction study only. Investigators will ...

Phase N/A

A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome

A 5 day course of fludarabine and cytarabine (FA) will be administered followed by full intensity conditioning regimen (Bucy) in the setting of allogeneic stem cell transplantation (SCT). The purpose of this study is to explore the antileukemic, immunosuppressive effects and safety of FA as the backbone of a conditioning ...

Phase N/A

Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia

PRIMARY OBJECTIVES: I. To test the hypothesis that shotgun metagenomics is not inferior to standard of care diagnostics in the detection of pathogens in patients with febrile neutropenia. SECONDARY OBJECTIVES: I. To establish a microbiological diagnosis with known or unknown pathogens in patients in whom standard care failed to yield ...

Phase N/A